MetaVia (NASDAQ:MTVA) Research Coverage Started at HC Wainwright

HC Wainwright initiated coverage on shares of MetaVia (NASDAQ:MTVA) in a research report report published on Monday morning, Marketbeat reports. The firm issued a buy rating and a $12.00 price objective on the stock. HC Wainwright also issued estimates for MetaVia’s Q4 2024 earnings at ($0.74) EPS, FY2024 earnings at ($3.87) EPS, Q1 2025 earnings at ($0.65) EPS, Q2 2025 earnings at ($0.57) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.65) EPS, FY2025 earnings at ($2.61) EPS, FY2026 earnings at ($2.73) EPS, FY2027 earnings at ($4.27) EPS and FY2028 earnings at ($4.58) EPS.

MetaVia Price Performance

MTVA opened at $2.03 on Monday. MetaVia has a twelve month low of $1.51 and a twelve month high of $6.75.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.